Evotec's Horizon Program Faces Reality Check as Shares Sink 18.5% in a Week
Veröffentlicht: 14.07.2026 um 03:04 Uhr, Redaktion boerse-global.de
Evotec's stock has been pummelled to the edge of its 52-week low, closing at €4.13 on Monday after a seven-day rout of 18.54%. The Hamburg-based biotech's dramatic slide came as its ambitious "Horizon" restructuring plan failed to stem mounting anxiety over delayed partner milestones and a deteriorating profit outlook. The share now sits just 2.84% above the trough of €4.02 hit in March, having wiped out nearly half its value from the November 2025 peak of €7.75.
The trigger for this latest leg down was a stark revision to 2026 guidance. Evotec now expects an operating loss between €70 million and €105 million, abandoning earlier hopes of a positive result. Roughly 40% of the revenue shortfall stems from milestone payments pushed into 2027, while another 45% reflects partnerships that have yet to materialise. The company's reliance on big pharma budgets has left it acutely exposed when clients tighten their purse strings.
In response, CEO Christian Wojczewski has resorted to radical surgery. Up to 800 jobs are being cut and four sites closed, with annual savings of €75 million targeted by the end of 2027. But the cure comes at a steep upfront cost: Evotec has earmarked around €100 million in restructuring expenses between 2026 and 2028. The cash position on 30 June 2026 stood at €465.6 million, while the market capitalisation has shrunk to just €895.07 million — a brutal reflection of how far confidence has eroded.
Should investors sell immediately? Or is it worth buying Evotec?
The technical picture offers little respite. The relative strength index sits at 29.6, deep in oversold territory, yet such readings often prove unreliable during fundamental reorientations. The shares trade 24.14% below their 200-day moving average of €5.44, and the 50-day average of €4.93 provides no nearby support. Annualised volatility has spiked to 57.40%, a level that demands strong nerves.
Adding to the uncertainty, Goldman Sachs holds 14.62% of Evotec's voting rights, with a conspicuously high proportion of financial instruments relative to physical shares. Market watchers speculate that the US bank may be running hedging or tactical positions, injecting an extra layer of unpredictability into the stock's movements.
All eyes now turn to the half-year report due in August. Investors will be looking for evidence that the cost-cutting programme is on track and, crucially, that the delayed partner income is genuinely deferred rather than permanently slashed. For now, Evotec is paying the price of its partner-dependent business model — and the recovery is nowhere in sight.
Ad
Evotec Stock: New Analysis - 14 July
Fresh Evotec information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer zu unseren Artikeln: Keine Anlageberatung, keine Kauf oder Verkaufsempfehlung. Angaben zu Kursen, Unternehmen und Märkten ohne Gewähr; Änderungen jederzeit möglich. Börsengeschäfte können zu hohen Verlusten führen. Unsere Beiträge werden ganz oder teilweise automatisiert mit Unterstützung von AI erstellt und geprüft.
